Markets
Luke Kawa

US stocks hang on to some gains on a topsy-turvy day for tariffs

The day was a microcosm of the year, with everyone’s heads spinning thanks to extremely volatile changes to US trade policy. This time, though, it was the judicial branch rather than the executive branch that created the whipsaw.

US stocks opened well in the green after a court order Wednesday evening saw many of President Trump’s tariffs blocked. But that wouldn’t stop the president from potentially pursuing other avenues to tax imports, and, by the way, that court order was overruled by another court before the day was out. Whew. 

Stocks closed well off their highs, with the S&P 500 up 0.4%, the Nasdaq 100 rising 0.2%, and the Russell 2000 gaining 0.3%.

Communications services was the lone S&P 500 sector ETF to close negative, while real estate, energy, utilities, and healthcare were prominent gainers.

Nvidia’s strong earnings and solid outlook released after the close on Wednesday were key to the index’s gains, with Wall Street excited about improving rack supply and its ability to generate revenues even without being able to access the Chinese market. The chip designer’s impressive results initially buoyed a lot of its peers, but that didn’t last. Most notably, CoreWeave, which was up double digits, completely fell out of bed to close down 9%.

Even though the blocked tariffs that didn’t stay blocked for a full day did not affect auto stocks, carmakers like Stellantis, Nissan, and Toyota put in big gains anyway.

Plane maker Boeing hit a 52-week high after CEO Kelly Ortberg said China would once again accept deliveries.

Meanwhile, Build-A-Bear rewarded bulls, hitting an all-time high after surging more than 20% on blowout earnings.

Best Buy’s earnings had the opposite effect, sending shares sharply lower as sales were lower than anticipated and management trimmed its full-year revenue forecast.

More Markets

See all Markets
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.